Besides the sensitive detection of SNVs and INDELs, gene fusions in ALK, RET, or ROS1 were detected in 2.9% of ctDNA-positive lung cancer cases, exemplifying the clinical applicability of an amplicon-based assay for the detection of novel fusions. This evidence concerns the gene ROS1 and lung carcinoma.